This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Researchers develop tunable system that harnesses the spread of cargo carried by gene drives Credit: Gerard Terradas, UC San Diego Powerful new geneticengineering methods have given scientists the potential to revolutionize several sectors of global urgency.
More broadly however, several advancements are on the horizon for cell and gene therapies in 2023. This includes the first potential approval of a CRISPR-based gene therapy called exa-cel , which is developed by CRISPR Therapeutics and Vertex Pharmaceuticals. AZ: Cell and gene therapies often come with a high price.
AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at GPR75, a protective gene identified by scientists at the Regeneron Genetics Centre. The post Regeneron, AZ team up on drugs for obesity “superpower” gene appeared first on.
Poseida is a clinical-stage biopharmaceutical firm that utilizes its unique non-viral geneengineering methods to develop innovative cell and gene therapies. Scientists working at Poseida Therapeutics. Photo courtesy of Poseida Therapeutics.
But scientists at the University of California (UC), Santa Barbara, believe fluoride may offer hope in the fight against antibiotic-resistant bacteria. Justin is replacing that with the gene for these fluoride exporters.” ” The use of low-concentration fluoride costs only about four cents per liter. ” Source link.
During this period, Nobel prize-winning German scientist Paul Ehrlich developed his lock-key hypothesis of molecules that specifically bind to cell receptors. Building on the success of cytokine-based immunotherapies, scientists continued to seek other areas where the immune system could be leveraged against tumours.
These resistance genes are commonly found on small circles of DNA called plasmids. They often carry genes to help the bacteria succeed by giving it a selective advantage, such as bacterial toxins or antibiotic resistance genes. The progeny viruses are released into the environment to await another host to infect.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content